Product Image

Contributor Information

  • Name Simon Langdon
  • Institute Cancer Research UK Edinburgh Centre
  • Primary citation Langdon et al. 1988. Cancer Res. 48(21):6166-72. PMID: 3167863

Tool Details

  • Tool name: PEO1 Cell Line
  • Tool type: Cell Lines
  • Organism: Human
  • Tissue: Ovary
  • Cancer type: Gynaecologic cancer; Ovarian cancer; oestrogen receptor positive; Ovarian adenocarcinoma
  • Morphology: Epithelial; islands of uniform polygonal cells
  • Growth properties: Adherent
  • Model: Tumourigenic
  • Model description: The cell line is tumourigenic in immunologically-deprived CBA mice
  • Conditional: Yes
  • Description: The PEO1 Cell Line is one of nine from the PE ovarian adenocarcinoma panel (derived from 4 patients at varying stages of ovarian cancer, isolated from various malignant sites, and at various treatment stages) which provides a model system for research into the mechanism of oestrogen action on ovarian adenocarcinoma tumour cells, and for the study of efficacy and toxicity of oestrogen protagonists. PEO1 is an adherent cell line derived from a malignant effusion from the peritoneal ascites of a patient with a poorly differentiated serous adenocarcinoma. The patient previously received cisplatin, 5-fluorouracil and chlorambucil treatment. PEO1 is tumourigenic in immunologically-deprived CBA mice. PEO1 exhibits good growth in semi-solid medium (agar). PEO1 is from the same patient as the PEO4 and PEO6 cell lines.
  • Research area: Cancer; Drug development
  • Cellosaurus ID: CVCL_2686
  • Additional notes: Please be aware that the originating laboratory of the PEO1 cell line acknowledges that PEO1 is both genetically unstable and derived from a heterogeneous population that was already present in the patient at the time of biopsy. This is evident in the literature (Cooke et al., 2010). Genetic differences within the PEO1 PEO4 and PEO6 cell lines suggest that PEO4 and PEO6 are not direct descendants of PEO1 but have diverged from a common ancestor

  • For Research Use Only

Target Details

Application Details


  • Format: Frozen
  • Growth medium: RPMI-1640 + 2mM Glutamine + 2mM Sodium Pyruvate + 10% Foetal Bovine Serum (FBS)
  • Volume: 1 ml
  • Storage conditions: Liquid Nitrogen
  • Shipping conditions: Dry ice
  • Mycoplasma free: Yes
  • Biosafety level: 2
  • Subculture routine: Split sub-confluent cultures (70-80%) 1:4 to 1:10 seeding at 2- 3 x 104 cells/cm2 using 0.05% trypsin or trypsin/EDTA; 5% CO2; 37C. Doubling time approximately 37 hours



  •   Cruz et al. 2017. Cancer Genomics Proteomics. 14(1):35-51. PMID: 28031236
  •   Coscia et al. 2016. Nat Commun. 7:12645. PMID: 27561551
  •   Matassa et al. 2016. Cell Death Differ. :. PMID: 27206315
  •   Szikriszt et al. 2016. Genome Biol. 17(1):99. PMID: 27161042
  •   Huang et al. 2015. Oncotarget. :. PMID: 26683361
  •   Nevedomskaya et al. 2015. J Proteome Res. :. PMID: 26629888
  •   Patel et al. 2015. Cell Oncol (Dordr): PMID: 26266765
  •   Hearn et al. 2015. Proc Natl Acad Sci U S A. :. PMID: 26162681
  •   Ren et al. 2015. J Steroid Biochem Mol Biol. 150:54-63. PMID: 25817828
  •   Huntoon et al. 2013. Cancer Res. 73(12):3683-91. PMID: 23548269
  •   Cooke SL et al. 2010 Oncogene 2,29(35):4905-13. PMID: 20581869
  •   Sakai W et al. 2009. Cancer Res.15, 69(16): 6381–6386. PMID: 19654294
  •   Langdon et al. 1990. Br J Cancer. 62(2):213-6. PMID: 2386737
  •   Langdon et al. 1988. Cancer Res. 48(21):6161-5. PMID: 3167862
  •   Langdon et al. 1988. Cancer Res. 48(21):6166-72. PMID: 3167863